Business Description
MiNK Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US6036931029
Description
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.38 | |||||
Equity-to-Asset | -2.94 | |||||
Debt-to-Equity | -0.21 | |||||
Debt-to-EBITDA | -0.2 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -10.9 | |||||
3-Year EPS without NRI Growth Rate | -4.4 | |||||
3-Year FCF Growth Rate | -15.8 | |||||
3-Year Book Growth Rate | 35 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 54.5 | |||||
9-Day RSI | 49.7 | |||||
14-Day RSI | 48.07 | |||||
6-1 Month Momentum % | -3.85 | |||||
12-1 Month Momentum % | -50 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.54 | |||||
Quick Ratio | 0.54 | |||||
Cash Ratio | 0.52 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.8 | |||||
Shareholder Yield % | 0.27 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -216.19 | |||||
ROIC % | -619.57 | |||||
ROC (Joel Greenblatt) % | -2104.43 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -1.66 | |||||
EV-to-Forward-EBIT | -2.09 | |||||
EV-to-EBITDA | -1.67 | |||||
EV-to-FCF | -2.47 | |||||
Earnings Yield (Greenblatt) % | -60.24 | |||||
FCF Yield % | -38.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INKT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MiNK Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.59 | ||
Beta | 0 | ||
Volatility % | 38.72 | ||
14-Day RSI | 48.07 | ||
14-Day ATR ($) | 0.05615 | ||
20-Day SMA ($) | 0.924723 | ||
12-1 Month Momentum % | -50 | ||
52-Week Range ($) | 0.75 - 2.15 | ||
Shares Outstanding (Mil) | 39.37 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
MiNK Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
MiNK Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
MiNK Therapeutics Inc Frequently Asked Questions
What is MiNK Therapeutics Inc(INKT)'s stock price today?
The current price of INKT is $0.92. The 52 week high of INKT is $2.15 and 52 week low is $0.75.
When is next earnings date of MiNK Therapeutics Inc(INKT)?
The next earnings date of MiNK Therapeutics Inc(INKT) is 2024-08-09 Est..
Does MiNK Therapeutics Inc(INKT) pay dividends? If so, how much?
MiNK Therapeutics Inc(INKT) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |